Sec Form 4 Filing - SEIDENBERG BETH C @ Vera Therapeutics, Inc. - 2024-09-18

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person SEIDENBERG BETH C 2. Issuer Name and Ticker or Trading Symbol Vera Therapeutics, Inc. [ VERA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120 3. Date of Earliest Transaction (MM/DD/YY) 09/18/2024 (Street) BRISBANE, CA94005 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Class A Common Stock 09/18/2024 S( 1 ) 1,177 D $ 42.0119 ( 2 ) 160,376 ( 3 ) ( 4 ) D Class A Common Stock 09/18/2024 S( 1 ) 1,476 D $ 42 4,012 ( 5 ) I See Footnote ( 6 ) Class A Common Stock 09/19/2024 S( 1 ) 13,823 D $ 42.3058 ( 7 ) 146,553 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirec t Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other SEIDENBERG BETH C C/O VERA THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 120 BRISBANE, CA94005 X Signatures /s/ Joseph R. Young, Attorney-in-Fact 09/20/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 19, 2024. ( 2 )The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.07, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. ( 3 )In prior reports, the Reporting Person reported indirect beneficial ownership of 1,949,295 shares of Class A Common Stock (the "Shares") held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and KPCB XVI Founders Fund, LLC ("XVI Founders"), whose managing member is KPCB XVI Associates, LLC ("XVI Associates"). On April 10, 2024, KPCB XVI and XVI Founders made a pro-rata in-kind distribution of 750,000 Shares without consideration to its members, including XVI Associates, and likewise on June 5, 2024, they made an additional pro-rata in-kind distribution of 1,199,295 Shares to its members, including XVI Associates. ( 4 )On April 10, 2024, April 12, 2024, June 5, 2024 and June 13, 2024, the Reporting Person received an aggregate of 161,553 Shares as part of a pro-rata in-kind distribution without consideration from KPCB XVI, XVI Founders and their managing member, XVI Associates. The Reporting Person is one of the five managing members of XVI Associates. ( 5 )On April 10, 2024 and June 5, 2024, an aggregate of 5,488 Shares were received as part of a pro-rata in-kind distribution without consideration from XVI Associates, the managing member of KPCB XVI and XVI Founders. The Reporting Person is one of the five managing members of XVI Associates. ( 6 )Shares are held by the Samuel B. Seidenberg Irrevocable Trust, established on July 1, 2013, for which the Reporting Person and her spouse serve as trustees. ( 7 )The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.79, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.